|
|
 |
|
Viewing report
|
|
|
AGI Therapeutics (28-Mar-2011)
Directors Deals Ltd, March 2011, Pages: 1
David Kelly, (Executive) Chief Financial Officer of AGI Therapeutics [market cap £3million] bought 550,000 shares at 0.045EUR, holding is now 655,000 shares; representing 0.972 percent of the shares on issue. Holding has increased 524 percent, the total trade value was £21,580 and the significance rating is 72/100.
Directors Deals monitors and analyses share transactions made by directors in the shares of their own company. We monitor 18,000 companies share transactions in 46 countries worldwide (32 in Europe, 7 in Asia, 2 in North America, 2 in Oceania, 2 in the Middle East & 2 in Africa).
|
|
|
|
